Vaccine-Induced Cellular Immune Responses Reduce Plasma Viral Concentrations after Repeated Low-Dose Challenge with Pathogenic Simian Immunodeficiency Virus SIVmac239
Open Access
- 15 June 2006
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 80 (12), 5875-5885
- https://doi.org/10.1128/jvi.00171-06
Abstract
The goal of an AIDS vaccine regimen designed to induce cellular immune responses should be to reduce the viral set point and preserve memory CD4 lymphocytes. Here we investigated whether vaccine-induced cellular immunity in the absence of any Env-specific antibodies can control viral replication following multiple low-dose challenges with the highly pathogenic SIVmac239 isolate. Eight Mamu-A*01-positive Indian rhesus macaques were vaccinated with simian immunodeficiency virus (SIV) gag, tat, rev, and nef using a DNA prime-adenovirus boost strategy. Peak viremia (P = 0.007) and the chronic phase set point (P = 0.0192) were significantly decreased in the vaccinated cohort, out to 1 year postinfection. Loss of CD4+ memory populations was also ameliorated in vaccinated animals. Interestingly, only one of the eight vaccinees developed Env-specific neutralizing antibodies after infection. The control observed was significantly improved over that observed in animals vaccinated with SIV gag only. Vaccine-induced cellular immune responses can, therefore, exert a measure of control over replication of the AIDS virus in the complete absence of neutralizing antibody and give us hope that a vaccine designed to induce cellular immune responses might control viral replication.Keywords
This publication has 81 references indexed in Scilit:
- The High-Frequency Major Histocompatibility Complex Class I Allele Mamu-B
*
17 Is Associated with Control of Simian Immunodeficiency Virus SIVmac239 ReplicationJournal of Virology, 2006
- Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cellsNature, 2005
- Deliberate removal of T cell help improves virus-neutralizing antibody productionNature Immunology, 2004
- Repeated Low-Dose Mucosal Simian Immunodeficiency Virus SIVmac239 Challenge Results in the Same Viral and Immunological Kinetics as High-Dose Challenge: a Model for the Evaluation of Vaccine Efficacy in Nonhuman PrimatesJournal of Virology, 2004
- Improved Protection of Rhesus Macaques against Intrarectal Simian Immunodeficiency Virus SIVmac251Challenge by a Replication-Competent Ad5hr-SIVenv/revand Ad5hr-SIVgagRecombinant Priming/gp120 Boosting RegimenJournal of Virology, 2003
- Determinants of HIV-1 Mutational Escape From Cytotoxic T LymphocytesThe Journal of Experimental Medicine, 2003
- Comparison of the efficacy of early versus late viral proteins in vaccination against SIVVaccine, 2002
- Protection against Simian Immunodeficiency Virus Vaginal Challenge by Using Sabin Poliovirus VectorsJournal of Virology, 2001
- High-resolutionHLA-DRBtyping using denaturing gradient gel electrophoresis and direct sequencingTissue Antigens, 1997
- Direct Observation of Vortex Dynamics in Superconducting Films with Regular Arrays of DefectsScience, 1996